Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | April 28, 2026 | April 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 28, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 17,159 |
Reported balance
After 2026-04-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-28 · Other · Acquired 5,314 · Balance 17,159 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 28, 2026. |
| Common shares without par valueSEC Table I · non-derivative | Direct | 104,291 |
Reported balance
Holding disclosure · report date 2026-04-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 104,291 |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 28, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2026 Filed Apr 29, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | OtherCommon shares without par value | 5,314 | $94.41 | $501,694.74 |
DisclosureSEC source: 0001783147-26-000009 · form4-04292026_090456.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 17,159 F1 · balance_after: Balance in the Abbott Laboratories Stock Retirement Trust as of April 28, 2026. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 613 | $115.58 | $70,850.54 |
DisclosureSEC source: 0001783147-26-000007 · form4-03042026_010311.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,291 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,630 | $116.26 | $538,283.80 |
DisclosureSEC source: 0001783147-26-000007 · form4-03042026_010311.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,904 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 57,512 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001783147-26-000002 · form4-02262026_110230.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,512 Underlying: Common Shares · 57,512 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,170 on February 24, 2027, 19,171 on February 24, 2028, and 19,171 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001783147-26-000002 · form4-02262026_110230.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,534 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 791 | $138.17 | $109,292.47 |
DisclosureSEC source: 0001415889-25-006786 · form4-03052025_120337.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,583 Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,598 | $135.87 | $760,600.26 |
DisclosureSEC source: 0001415889-25-006786 · form4-03052025_120337.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,374 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 39,896 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005897 · form4-02272025_110242.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,896 Underlying: Common Shares · 39,896 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,298 on February 25, 2026, 13,299 on February 25, 2027, and 13,299 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005897 · form4-02272025_110242.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,972 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 676 | $118.50 | $80,106.00 |
DisclosureSEC source: 0001415889-24-006410 · form4-03052024_120338.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,260 Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,862 | $120.05 | $703,733.10 |
DisclosureSEC source: 0001415889-24-006410 · form4-03052024_120338.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,936 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 39,734 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005105 · form4-02232024_100217.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,734 Underlying: Common Shares · 39,734 shares Expires 2034-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,244 on February 21, 2025, 13,245 on February 21, 2026, and 13,245 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005105 · form4-02232024_100217.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,798 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 717 | $100.77 | $72,252.09 |
DisclosureSEC source: 0001415889-23-003912 · form4-03032023_120314.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,224 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,926 | $99.77 | $591,237.02 |
DisclosureSEC source: 0001415889-23-003912 · form4-03032023_120314.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,941 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 48,344 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003057 · form4-02232023_120200.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,344 Underlying: Common Shares · 48,344 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,114 on February 17, 2024, 16,115 on February 17, 2025, and 16,115 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003057 · form4-02232023_120200.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,867 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,245 | $108.84 | $135,505.80 |
DisclosureSEC source: 0001415889-22-008158 · form4-08032022_090813.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,608 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,112 | $122.41 | $503,349.92 |
DisclosureSEC source: 0001415889-22-002197 · form4-03022022_040347.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,853 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 793 | $116.79 | $92,614.47 |
DisclosureSEC source: 0001415889-22-001742 · form4-02232022_050234.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,365 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 73,696 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001742 · form4-02232022_050234.xml · derivative · entry 5 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,696 Underlying: Common Shares · 73,696 shares Expires 2032-02-17 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001742 · form4-02232022_050234.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,158 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,245 | $120.98 | $150,620.10 |
DisclosureSEC source: 0001415889-21-003773 · form4-08032021_020823.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,345 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,116 | $121.58 | $257,263.28 |
DisclosureSEC source: 0001415889-21-001210 · form4-03022021_040343.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,590 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $121.84 | $48,734.00 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,706 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 780 | $123.04 | $95,971.20 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,106 Read SEC document |
| February 22, 2021 Filed Feb 24, 2022 01:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $119.31 | $47,722.68 |
DisclosureSEC source: 0001415889-22-001742 · form4-02232022_050234.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,965 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 69,266 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · derivative · entry 5 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,266 Underlying: Common Shares · 69,266 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,088 on February 19, 2022, 23,089 on February 19, 2023, and 23,089 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,886 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 505 | $128.49 | $64,887.45 |
DisclosureSEC source: 0001415889-21-000751 · form4-02182021_020211.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,373 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,009 | $128.23 | $129,384.07 |
DisclosureSEC source: 0001415889-21-000751 · form4-02182021_020211.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,244 | $100.64 | $125,196.16 |
DisclosureSEC source: 0001179110-20-008703 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,887 Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $84.93 | $33,972.00 |
DisclosureSEC source: 0001179110-20-002281 · edgar.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,131 Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 780 | $87.45 | $68,211.00 |
DisclosureSEC source: 0001179110-20-002281 · edgar.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,531 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 87,334 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002281 · edgar.xml · derivative · entry 5 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,334 Underlying: Common shares · 87,334 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,111 on February 21, 2021, 29,111 on February 21, 2022, and 29,112 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002281 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,311 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,019 | $88.97 | $90,660.43 |
DisclosureSEC source: 0001179110-20-001897 · edgar.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,985 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,004 | $89.66 | $90,018.64 |
DisclosureSEC source: 0001179110-20-001897 · edgar.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,004 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,020 | $89.66 | $91,453.20 |
DisclosureSEC source: 0001179110-20-001897 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,008 Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 60,912 | $0.00 Strike: $86.86 | $0.00 |
DisclosureSEC source: 0001179110-19-009136 · edgar.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,912 Underlying: Common shares · 60,912 shares Expires 2029-07-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,304 on August 1, 2020, 20,304 on August 1, 2021, and 20,304 on August 1, 2022. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 8,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009136 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,028 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.